The guidance cut to $46M-$48M implies a sharp deceleration in H2 2026 vs the prior outlook, suggesting the commercial expansion is not yet translating to expected revenue. Monitor Q4 results for whether the TriNav Advance launch and CMS reimbursement changes can re-accelerate growth in 2027.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $2.85entry
- T+1 · 6d ago −19.30%α −20.62% · $2.30
- T+5 · due 9h ago Pending
- T+5 · todayOpen
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TriSalus Life Sciences reported Q3 2026 revenue of $12.9M (+11.3% YoY), above the $14.0M consensus, but revised full-year 2026 revenue guidance down to $46M-$48M (2-6% growth vs 2025), well below the prior $54M-$57M range. CMS finalized favorable 2027 reimbursement rate increases for PEDD procedures, but the guidance cut signals slower-than-expected commercial ramp.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $12.9M, +11.3% YoY from $11.6M
- Full-year 2026 revenue guidance revised to $46M-$48M from prior $54M-$57M
- GAAP diluted EPS -$0.15 vs -$0.96 YoY; consensus was -$0.13
- Gross margin 86.2% vs 83.5% YoY
- Operating loss -$7.7M improved from -$9.0M YoY
- Cash $41.1M at Sep 30, 2026; raised $46M in Q1 equity offering
- CMS finalized 2027 PEDD reimbursement increase from ~$11,794 to ~$20,910 per procedure
- FDA clearance received for TriNav Advance enabling PEDD in small distal vessels
Financial Impact
Revenue guidance cut by ~$8M-$9M from prior midpoint; Q3 revenue $12.9M missed $14.0M consensus by 7.9%
Risk Factors
- Revised guidance implies H2 revenue well below prior expectations; commercial team productivity ramping slower than anticipated
- Cash burn continues; $41.1M at Sep 30 may require additional financing before reaching profitability
- Dependence on CMS reimbursement changes and FDA clearance for growth inflection
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-072513 |
| Document: tlsi-20261110.htm | 0001628280-26-072513 |
| Document: 0001628280-26-072513-index-headers.html | 0001628280-26-072513 |
| Document: 0001628280-26-072513-index.html | 0001628280-26-072513 |
| Document: 0001628280-26-072513.txt | 0001628280-26-072513 |
| 8-K Data (Synthetic) | 0001628280-26-072513 |
Track record
7 reports on TLSI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 17, 2026today Insider Cluster Neutral 3/10 Entry $2.20 Now $2.30 +4.32% settles Nov 19
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.27 Now $2.30 +1.10% settles Nov 18
- Nov 10, 20267d ago 8-K Bearish 6/10 Viewing Entry $2.85 to $2.30 Now $2.30 +19.47% ▲ +19.30% +20.62% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $3.64 to $3.77 Now $2.30 −36.95% ▲ +3.57% +3.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bullish 4/10 Entry $3.64 to $3.77 Now $2.30 −36.95% ▲ +3.57% +3.03% vs SPY
- Mar 11, 202635w ago Insider Cluster Neutral 3/10 Entry $4.16 to $4.10 Now $2.30 −44.83% ▼ −1.44% +0.04% vs SPY
- Mar 5, 202636w ago 8-K Bullish 8/10 Entry $4.47 to $4.62 Now $2.30 −48.60% ▲ +3.36% +2.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers